Previous 10 | Next 10 |
2023-12-21 10:00:01 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector For further details see: Cassava Sciences, Myomo among healthcare movers
2023-12-21 06:45:03 ET Bank of America Securities analyst issues BUY recommendation for ANNX on December 21, 2023 06:03AM ET. ANNX was trading at $2.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - ...
2023-12-20 17:36:06 ET More on Annexon Biosciences Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences Financial information for Annexon Biosciences For further details see: Annexon stock jumps on pr...
BRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the p...
Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians ARCHER II, a Global Sham-Controlled Trial Supporting a Potentially Faster Path to Registration, Expected to Initiate ...
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across Cohorts with No Serious Adverse Events Tablet Formulation of ANX1502 Expected...
BRISBANE, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president...
2023-11-13 06:39:43 ET More on Annexon: Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences Financial information for Annexon Biosciences For further details see: Annexon GAAP EPS of -$0.43 beats by ...
Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ANX005 Phase 3 Pivotal Data in GBS On Track for First Half of 2024 ANX007 Awarded F...
BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devasting inflammatory-related diseases, today announced that Douglas Love, president and chi...
News, Short Squeeze, Breakout and More Instantly...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE N...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First Targeted Therapy Approved for the Treatment of GBS BRISBANE, Calif., June 18, 2024 (GLOBE...